Mr Mrs Miss Ms Dr Other

Ms
Roxna
Kapadia

Patent Director

London Office

Life sciences

Telephone. +44 20 7776 5100
Email. [email protected]

Experience

Roxna is a UK and European qualified patent attorney with a technical background in Microbiology and Immunology. She has in-depth knowledge and experience with viral cancer therapeutics, antibodies, microbiome, stem cells, immunotherapy, genetics and food science. Roxna has in-house patent experience working at the small biotechnology company Oncolytics Biotech Inc. and at the multinational company General Electric Healthcare and Merck Sharp & Dohme.

Roxna has experience working before the EPO, UKIPO and WIPO, including drafting and filing applications, prosecution and EPO oppositions and appeals. Roxna also has extensive experience with IP due diligence, validity opinions and FTO analysis. Having worked both in house and in private practice, Roxna is well placed to provide business focused strategic intellectual property advice to her clients.

Roxna is a named inventor on a patent for a method of purifying viruses using gel permeation chromatography. Roxna developed and ran industry-focused intellectual property courses in London UK. In particular Roxna has taught Freedom to Operate courses for the Life Sciences and Pharmaceutical Industry.

Having grown up in Canada and worked in Switzerland, Roxna is fluent in English and French.

Qualifications

Patent Attorney

Chartered (UK)
Europe


BSC

Microbiology and Immunology

MSC

Immunology

MSC

Management of Intellectual Property

Publications

Divergent Roles of Toll-like Receptor 2 in Response to Lipoteichoic acid and Staphylococcus aureus In Vivo.

View publication online

The Use of Immunohistochemistry to Determine Oncolytic Reovirus Distribution and Replication In-Human Tumors.

View publication online

Related News

The UPC has opened its doors! See the latest updates and advice on the UPC here.

The European patent system has had the biggest change in a generation – on 1 June 2023 the Unified Patent Court (UPC) and a new “unitary patent” or “European patent …

Read article

Managing Intellectual Property IP Stars 2023

After months of research, Managing IP has published the IP Stars list for 2023. HGF is delighted to have 23 attorneys from England, Scotland, Ireland, Netherlands and Germany recognised and …

Read article

Profiting from Innovation Within Product Platforms

Innovative businesses should seek to maximise the value they obtain from working collaboratively within a product platform ecosystem. A well-defined IP strategy can help achieve this while increasing total innovation …

Read article
Event - 25th May 2023

New seminar series in Salzburg, Dresden and Hamburg

HGF is organising a new German-speaking seminar series in Salzburg, Dresden, and Hamburg starting May 25 2023. Dates May 25, 2023 at 17:30 – Salzburg June 1 2023 at 17:30 …

Event details

Can Artificial Intelligence save the NHS?

In recent months, it has been almost impossible to escape reports of the staffing crisis in the NHS and the impact this is having on the services the NHS can …

Read article

Spotting innovation in digital health – and can you patent it?

Intellectual Property (IP) can add significant value to your business, providing a competitive edge over the market, as well as demonstrating sound business planning to help secure investment. There are …

Read article

Innovation at the heart of UK medtech strategy

The UK Department of Health and Social Care has recently published the government’s first ever medical technology strategy in an effort to accelerate access to innovative technologies. The strategy document …

Read article

How medtech start-ups can supercharge their IP for fundraising

Why is IP important for fundraising? Intellectual property (IP) rights underpin the value of most medtech start-up companies. IP rights include patents, design rights, trade marks, copyright and trade secrets …

Read article

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.